Patients With Cryptogenic Hypertransaminasemia (LIFT)
From the Gut to the Liver: Unraveling the Role of Bacterial Translocation in Cryptogenic Hypertransaminasemia
Persistent unexplained elevation of serum aminotransferases (ALT and AST) remains undiagnosed in a subset of patients despite a comprehensive diagnostic work-up. Increasing evidence suggests that alterations in the gut-liver axis, including intestinal dysbiosis, increased intestinal permeability, and bacterial translocation, may contribute to liver inflammation and hepatocellular injury. Bacterial components such as lipopolysaccharide (LPS) may reach the portal circulation and activate hepatic immune pathways through receptors including CD14 and Toll-like receptor 4 (TLR4).
This study aims to investigate the potential role of bacterial translocation in patients with unexplained persistent hypertransaminasemia undergoing liver biopsy. Standard histological evaluation will be integrated with immunohistochemical and molecular analyses of liver biopsy specimens to assess markers associated with bacterial translocation, including bacterial DNA, LPS, and soluble CD14 (sCD14). The study may help clarify the underlying mechanisms of otherwise unexplained hypertransaminasemia and identify potential biomarkers for future clinical use.
調査の概要
状態
詳細な説明
The study will involve the collection of clinical, demographic, anthropometric, laboratory, medication, and imaging data from patients with persistent unexplained hypertransaminasemia. Relevant laboratory parameters will include liver function tests, metabolic parameters, complete blood count, glycated hemoglobin, and hepatitis B and C serological markers.
Additional biological samples will be collected during routine clinical procedures, including a 10 mL blood sample, a liver tissue specimen obtained during clinically indicated liver biopsy, and a stool sample. Liver tissue will undergo standard histological evaluation and additional immunohistochemical analyses. Blood and stool samples will be analyzed to investigate markers of bacterial translocation, intestinal microbiota composition, and inflammatory profiles, with the aim of better characterizing the gut-liver axis and its potential role in unexplained hypertransaminasemia.
All clinical data and biological samples will be collected only after obtaining written informed consent from participants, in accordance with the approval of the competent Ethics Committee. Biological samples and study-related data will be stored and processed at Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前：Francesca Romana Ponziani
- 電話番号：3471227242
- メール：francescaromana.ponziani@policlinicogemelli.it
研究連絡先のバックアップ
- 名前：Elisabetta Creta
- 電話番号：3480778584
- メール：elisabetta.creta@policlinicogemelli.it
研究場所
-
-
-
Roma、イタリア、00168
- Fondazione Policlinico Universitaro A. Gemelli IRCSS,UOC Medicina Interna e Gastroenterologia,Largo A. Gemelli,
-
コンタクト：
- Francesca Romana Ponziani
- 電話番号：3471227242
- メール：francescaromana.ponziani@policlinicogemelli.it
-
コンタクト：
- Elisabetta Creta
- 電話番号：3480778584
- メール：elisabetta.creta@policlinicogemelli.it
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
The study aims to enroll 30 patients with cryptogenic hypertransaminasemia and a control group of 10 participants with normal aminotransferase levels who are undergoing surgical resection of benign liver lesions in the setting of otherwise healthy liver parenchyma.
説明
Inclusion Criteria:
- Age ≥ 18 years.
- Persistent cryptogenic hypertransaminasemia (elevated ALT and/or AST levels) documented for at least 6 months. For the control group only: normal aminotransferase levels.
- No identifiable etiology after a comprehensive clinical, laboratory, and instrumental evaluation.
- Ability to provide written informed consent.
Exclusion Criteria:
- Age < 18 years.
- Histologically documented metabolic dysfunction-associated steatotic liver disease (MASLD).
- Alcohol-related liver disease or active alcohol consumption.
- Active viral hepatitis.
- Hereditary hemochromatosis or other known genetic liver diseases.
- Adverse reactions to potentially hepatotoxic drugs.
- Celiac disease, thyroid disorders, rhabdomyolysis, or known muscle diseases.
- Ongoing acute infections.
- Systemic antibiotic or probiotic therapy within the 3 months preceding enrollment.
- Ongoing immunosuppressive therapy.
- Active malignancy.
- Pregnancy.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 観測モデル：COHORT
- 時間の展望：PROSPECTIVE
コホートと介入
グループ/コホート |
|---|
|
Patients with cryptogenic hypertransaminasemia
Patients with cryptogenic hypertransaminasemia will undergo the collection of additional biological samples during routine clinical procedures. These will include an additional 10 mL blood sample, a liver tissue specimen for histological and immunohistochemical analysis, and a stool sample. The collection of these biological specimens will be performed as part of the routine clinical management and diagnostic work-up of patients undergoing evaluation for persistent hypertransaminasemia. |
|
Healthy Controls
Control participants will be individuals with normal serum aminotransferase levels who are undergoing surgical resection of benign liver lesions in the setting of otherwise healthy liver parenchyma. During routine clinical procedures, an additional 10 mL blood sample will be collected, together with a liver tissue specimen obtained during surgery for histological and immunohistochemical analysis. Participants will also be asked to provide a stool sample. The collection of these biological specimens will be performed in conjunction with routine clinical care and the surgical procedure. |
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Hepatic LPS Expression
時間枠：30-45 month
|
Immunohistochemical assessment of lipopolysaccharide (LPS) expression in liver tissue obtained from patients with cryptogenic hypertransaminasemia and control participants. |
30-45 month
|
|
Hepatic LBP Expression
時間枠：30-45 month
|
Immunohistochemical assessment of lipopolysaccharide-binding protein (LBP) expression in liver tissue obtained from patients with cryptogenic hypertransaminasemia and control participants. |
30-45 month
|
|
Hepatic CD14 Expression
時間枠：30-45 month
|
Immunohistochemical assessment of CD14 expression in liver tissue obtained from participants with cryptogenic hypertransaminasemia and control participants. |
30-45 month
|
|
Hepatic MD-2 Expression
時間枠：30-45 month
|
Immunohistochemical assessment of myeloid differentiation factor 2 (MD-2) expression in liver tissue obtained from participants with cryptogenic hypertransaminasemia and control participants. |
30-45 month
|
|
Hepatic TLR2 Expression
時間枠：30-45 month
|
Immunohistochemical assessment of Toll-like receptor 2 (TLR2) expression in liver tissue obtained from participants with cryptogenic hypertransaminasemia and control participants. |
30-45 month
|
|
Hepatic TLR4 Expression
時間枠：30-45 month
|
Immunohistochemical assessment of Toll-like receptor 4 (TLR4) expression in liver tissue obtained from patients with cryptogenic hypertransaminasemia and control participants. |
30-45 month
|
|
Hepatic TLR5 Expression
時間枠：30-45 month
|
Immunohistochemical assessment of Toll-like receptor 5 (TLR5) expression in liver tissue obtained from patients with cryptogenic hypertransaminasemia and control participants. |
30-45 month
|
協力者と研究者
捜査官
- 主任研究者：Francesca Romana Ponziani、Fondazione Policlinico Universitario Agostino Gemelli IRCCS
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。